
|Articles|May 26, 2021
Thoma Bravo to Acquire Greenphire
Advertisement
Thoma Bravo has announced that it has reached an agreement to acquire Greenphire from The Riverside Company. The deal, which is subject to customary regulatory approvals, is expected to close in the second quarter of this year. Jim Murphy, CEO of Greenphire, will continue to lead the company along with the existing management team in King of Prussia, PA.
Jefferies LLC and AGC Partners are serving as financial advisor to Greenphire and Jones Day is serving as legal counsel. William Blair is serving as financial advisor to Thoma Bravo and Kirkland & Ellis, LLP is serving as legal counsel.
Financial details were not disclosed.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
2
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Breaking the Efficacy Ceiling in IBD and Beyond
5



